Previous Close | 5.23 |
Open | 5.32 |
Bid | 5.03 x 100 |
Ask | 5.26 x 100 |
Day's Range | 5.11 - 5.32 |
52 Week Range | 2.51 - 6.97 |
Volume | |
Avg. Volume | 133,339 |
Market Cap | 68.982M |
Beta (5Y Monthly) | 1.12 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.91 |
Earnings Date | May 06, 2024 - May 10, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement ≥ 3 Points) including: 9.29 Points for Patients at the Two-Year Milestone 8.08 Points for ...
IRVINE, CA / ACCESSWIRE / April 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that additional topline efficacy data from ...
Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve® PMA application seeking FDA approval for the VenoValve on track to be filed in Q4 of 2024 IRVINE, CA / ACCESSWIRE ...